Samsung Biologics has renegotiated its manufacturing agreement with Baxter Healthcare, increasing Baxter’s payments to Samsung to over US$223 million through the end of 2034, up from an initial US$15m. The specifics of the products Samsung will manufacture for Baxter remain undisclosed.
This follows Samsung Biologic’s announcement on 7 February 2024 that it had partnered with Lego Chem Biosciences to develop and manufacture ADCs.